Q&A With Robert Giugliano From Brigham and Women's: Approval of PCSK9 Inhibitors Still Leaves Some Questions

While PCSK9 inhibitors have been shown to help patients lower their cholesterol levels, there are still questions about potential side effects as well as when and how the medication will be made affordable and available to patients.

Robert Giugliano, MD, from Brigham & Women's Hospital in Boston said that while there are still questions the immediate benefit of the medications should be given great consideration during the treatment process. Giugliano was one of thousands of cardiologists in attendance at the European Soceity of Cardiology's Annual Congress in London and said many doctors on both sides of the Atlantic agreed that it can be a valuable tool when it is made largely available to patients.